Agios Pharmaceuticals Ownership | Who Owns Agios Pharmaceuticals?

Overview Forecast RevenueFinancials Chart Transcripts

Agios Pharmaceuticals Ownership Summary

Agios Pharmaceuticals is owned by 108.74% institutional investors, 1.09% insiders. Blackrock funding, inc. /de is the largest institutional shareholder, holding 9.93% of AGIO shares. BB Biotech AG Ord is the top mutual fund, with 6.34% of its assets in Agios Pharmaceuticals shares.

AGIO Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Agios Pharmaceuticals	108.74%	1.09%	-9.83%
Sector	Healthcare Stocks	35.49%	11.78%	52.72%
Industry	Biotech Stocks	34.84%	11.71%	53.45%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Blackrock funding, inc. /de	5.75M	9.93%	$194.69M
Farallon capital management	5.68M	9.80%	$192.29M
Vanguard group	5.59M	9.62%	$152.28M
Blackrock	4.86M	8.55%	$209.52M
Bellevue group	3.71M	6.41%	$149.11M
State street	3.36M	5.80%	$113.72M
Armistice capital	2.72M	4.68%	$91.88M
Erste asset management gmbh	2.70M	4.67%	$80.09M
D. e. shaw	2.68M	4.62%	$90.70M
Paradigm biocapital advisors lp	2.67M	4.61%	$107.32M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Lynx1 capital management lp	2.61M	13.96%	$88.35M
Caligan partners lp	1.13M	5.95%	$45.41M
Commodore capital lp	2.34M	4.58%	$93.86M
Cutter capital management, lp	301.62K	4.06%	$9.91M
Foresite capital management vi	525.00K	3.86%	$17.76M
Bioimpact capital	1.31M	3.41%	$44.19M
Bellevue group	3.71M	3.10%	$149.11M
Paradigm biocapital advisors lp	2.67M	3.05%	$107.32M
Exome asset management	125.06K	2.19%	$4.23M
Knott david m jr	93.06K	1.87%	$3.15M

Top Buyers

Holder	Shares	% Assets	Change
Lynx1 capital management lp	2.61M	13.96%	2.53M
Paradigm biocapital advisors lp	2.67M	3.05%	1.53M
T. rowe price investment management	1.49M	0.03%	1.49M
D. e. shaw	2.68M	0.05%	843.98K
Farallon capital management	5.68M	1.10%	524.50K

Top Sellers

Holder	Shares	% Assets	Change
Macquarie group	-	-	-1.96M
Jefferies financial group	-	-	-1.50M
Tcg crossover management	-	-	-1.18M
Bvf inc/il	-	-	-1.07M
Polar capital	-	-	-1.00M

New Positions

Holder	Shares	% Assets	Change	Value
Vanguard fiduciary trust	382.02K	0.00%	382.02K	$12.92M
Arrowstreet capital, limited partnership	250.46K	0.00%	250.46K	$8.47M
Schonfeld strategic advisors	200.06K	0.05%	200.06K	$6.77M
Eversept partners, lp	200.00K	0.36%	200.00K	$6.77M
Axa investment managers	177.68K	0.02%	177.68K	$7.13M

Sold Out

Holder	Change
National bank of canada /fi/	-1.00
Dinuzzo private wealth	-1.00
Global financial private client	-3.00
Riggs asset managment	-3.00
Hfm investment advisors	-3.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	246	-3.91%	63,038,205	2.90%	108	0.98%	123	-13.99%	76	7.04%
Dec 31, 2025	165	-31.82%	34,473,117	-45.71%	59	0.49%	89	-24.58%	49	-28.99%
Sep 30, 2025	229	9.05%	60,859,306	3.40%	105	1.02%	111	4.72%	67	-6.94%
Jun 30, 2025	217	-3.56%	61,654,515	3.33%	106	0.99%	108	-5.26%	76	5.56%
Mar 31, 2025	223	-4.29%	59,949,912	0.23%	104	0.95%	113	-12.40%	71	2.90%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
BB Biotech AG Ord	3.71M	6.34%	124.59K
State Street® SPDR® S&P® Biotech ETF	2.15M	3.62%	-21.27K
Vanguard Total Stock Mkt Idx Inv	1.88M	3.20%	19.74K
Vanguard US Total Market Shares ETF	1.79M	3.12%	2.35K
Macquarie Small Cap Core I	1.43M	2.46%	-107.41K
Delaware Small Cap Core I	1.38M	2.42%	-8.55K
Vanguard Small Cap Index	1.35M	2.31%	27.64K
iShares Russell 2000 ETF	1.33M	2.23%	11.19K
Nomura US Small Cap Core Equity	1.18M	1.99%	1.18M
Nomura Small Cap Core I	1.18M	1.99%	-37.63K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Apr 02, 2026	Burns James William	Chief Legal Officer	Sell	$113.85K
Apr 02, 2026	Gheuens Sarah	Chief Medical Officer	Sell	$102.05K
Apr 02, 2026	Jones Cecilia	Chief Financial Officer	Sell	$109.02K
Apr 02, 2026	Milanova Tsveta	Chief Commercial Officer	Sell	$113.22K
Apr 02, 2026	Viswanadhan Krishnan	Chief Corp Dev & Strategy	Sell	$102.71K

Insider Transactions Trends

Date	Buy	Sell
2026 Q1	-	21
2025 Q4	-	11
2025 Q3	-	9
2025 Q2	-	7
2025 Q1	-	16

AGIO Ownership FAQ

Who Owns Agios Pharmaceuticals?

Agios Pharmaceuticals shareholders are primarily institutional investors at 108.74%, followed by 1.09% insiders and -9.83% retail investors. The average institutional ownership in Agios Pharmaceuticals's industry, Biotech Stocks , is 34.84%, which Agios Pharmaceuticals exceeds.

Who owns the most shares of Agios Pharmaceuticals?

Agios Pharmaceuticals’s largest shareholders are Blackrock funding, inc. /de (5.75M shares, 9.93%), Farallon capital management (5.68M shares, 9.80%), and Vanguard group (5.59M shares, 9.62%). Together, they hold 29.35% of Agios Pharmaceuticals’s total shares outstanding.

Does Blackrock own Agios Pharmaceuticals?

Yes, BlackRock owns 8.55% of Agios Pharmaceuticals, totaling 4.86M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 209.52M$. In the last quarter, BlackRock increased its holdings by 200.91K shares, a 4.31% change.

Who is Agios Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Lynx1 capital management lp is Agios Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 13.96% of its assets in 2.61M Agios Pharmaceuticals shares, valued at 88.35M$.

Who is the top mutual fund holder of Agios Pharmaceuticals shares?

BB Biotech AG Ord is the top mutual fund holder of Agios Pharmaceuticals shares, with 6.34% of its total shares outstanding invested in 3.71M Agios Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools